Everolimus
Test Mnemonic
EVEROL
CPT Codes
- 80169 - QTY (1)
LOINC ®
50544-6
Aliases
- Afinitor
- Certican
- Zortress
Performing Laboratory
Cleveland Clinic Laboratories
Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 1 mL | Whole blood | EDTA (Lavender) | Refrigerated | Collect prior to next dose |
Minimum Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 0.5 mL |
Stability
| Environmental Condition | Description |
|---|---|
| Ambient | 1 day |
| Refrigerated | 2 weeks |
| Frozen | 2 weeks |
Days Performed
Sun - Sat
Turnaround Time
1 - 2 days
Methodology
| Name | Description |
|---|---|
| Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) |
Reference Range
| Everolimus | |||||
|---|---|---|---|---|---|
| Sex | Age From | Age To | Type | Range | Range Unit |
| Years | 99 Years | Normal | 3.0 - 8.0 | ng/mL | Years | 99 Years | Urgent | >30.0 | ng/mL |
Special Info
Collect immediately prior to next dose.
Clinical Info
Everolimus, marketed as Zortress, is FDA approved for prophylaxis of organ rejection in patients at low-moderate immunologic risk receiving renal transplants. The suggested therapeutic range for this purpose is 3-8 ng/mL with the short term target range of 6-12 ng/mL. This range is based on a predose (trough) specimen in patients who are also receiving cyclosporine. Everolimus, marketed as Afinitor, is FDA approved for the treatment of advanced renal cell cancer (RCC), after sunitinib or sorafenib failure; treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis, in patients who are not candidates for curative surgical resection; treatment of advanced, metastatic or unresectable pancreatic neuroendocrine tumors (PNET). The suggested therapeutic range for treatment of SEGA is 5-10 ng/mL, which is based on a predose (trough) specimen.